ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,100, issued on May 12, was assigned to SOTIO BIOTECH A.S. (Prague).
"Humanized CLDN18.2 antibodies" was invented by Lukas Bammert (Basel, Switzerland), Lenka Kyrych Sadilkova (Horomerice, Czech Republic), Lorenz Waldmeier (Basel, Switzerland), Roger Beerli (Adlikon bei Regensdorf, Switzerland) and Ulrich Moebius (Gauting, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides humanized antibodies binding to CLDN18.2 with a high affinity. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses."
The patent was filed on Dec. 7, 2020, und...